Program
To view the program and presentations from the 5th Global Forum on TB Vaccines, click on the “Show Details” button for the sessions you wish to view. Please note that only presentations that the organizers have been given permission to share are posted on this page.
Click here to download the 5th Global Forum program and abstract book.
Click here to read the 5th Global Forum meeting report, published in Tuberculosis
Tuesday, 20 February 2018
10:30 – 12:15
Shahjehan
Opening Session
Co-Chairs: Danilo Casimiro, former Chief Scientific Officer, Aeras (USA) | Soumya Swaminathan, former Director-General, Indian Council of Medical Research (India) | David Lewinsohn, Chair, Stop TB Partnership Working Group on New TB Vaccines (USA) | Nick Drager, Executive Director, TuBerculosis Vaccine Initiative (Netherlands)
- Overview of the TB epidemic globally and in India (video)
Soumya Swaminathan, Deputy Director General of Programmes, World Health Organization (Switzerland) - Civil society perspective on the need for new TB vaccines (video)
Blessina Kumar, Global Coalition of TB Activists (India) - Access and affordability for new TB vaccines (video)
Hendrik Bekedam, World Health Organization (WHO) Representative to India, WHO Country Office (India) - The potential public health impact of new TB vaccines (video)
Richard White, Professor, London School of Hygiene and Tropical Medicine and Director, TB Modelling and Analysis Consortium (UK) - Partnerships and collaboration in TB vaccine R&D (video)
Renu Swarup, Senior Advisor, Department of Biotechnology, Ministry of Science & Technology (India) - India’s commitment to end TB (video)
Sunil Khaparde, Deputy Director General (TB), Ministry of Health & Family Welfare, Government of India (India)
12:15 - 13:00
Shahjehan
Keynote Address
Why we need a vaccine to control TB and what we need to learn to develop an effective vaccine (video)
Barry Bloom, Joan L. and Julius H. Jacobson Research Professor of Public Health, Harvard University (USA)
13:00 – 14:00
Rani Bagh Lawn
Lunch
14:00 – 16:00
Shahjehan
Plenary Session 1: Increasing Probability of Success and Maximizing Impact
Co-Chairs: Ann Ginsberg, Aeras (USA) | Gagandeep Kang, Translational Health Science and Technology Institute (India)
- Vaccine strategies to address drug-resistant tuberculosis
Gavin Churchyard, The Aurum Institute (South Africa) - Decision-making in TB vaccine development: the stage-gate process
Georges Thiry, Joint Aeras/Tuberculosis Vaccine Initiative Working Group on Stage-Gates (France)
- Can biomarkers advance the development of new TB vaccines?
Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK) - Human TB challenge – you can do that?
Eric Rubin, Harvard T.H. Chan School of Public Health (USA) - Enriching cohorts for smaller, quicker, more efficient TB vaccine studies
Dereck Tait, Aeras (South Africa)
Presented by Ann Ginsberg (Aeras)
16:15 – 17:45
Roshanara
Poster Discussion 1: Basic Vaccine Concepts and Correlates of Protective Immunity
Coffee/tea to be served in the session rooms
Facilitators: David Lewinsohn, Oregon Health & Science University (USA) | Vinay Kumar Nandicoori, National Institute of Immunology (India)
- Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) exacerbates TB infection after aerosol challenge in mice – implications for host-directed therapy
Rasmus Mortensen, Statens Serum Institute (Denmark) - Deciphering the role of VapBC TA modules in virulence and pathogenesis of Mycobacterium tuberculosis
Sakshi Agarwal, Translational Health Science and Technology Institute (India)
- Mycobacterium tuberculosis hbhA and mtp deletion elicits unique canonical pathways during early infection in THP-1 differentiated macrophages
Suventha Moodley, University of KwaZula-Natal (South Africa) - Targeting ClpB abrogates stress tolerance in Mycobacterium tuberculosis and hence its growth and infectivity
Prajna Tripathi, National Institute of Immunology (India) - Circulating HLA-DR+IFNγhiIL-17hiCD4+T effectors resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis
Asma Ahmed, Indian Institute of Science (India) - PPM, a novel Mycobacterium tuberculosis (Mtb) antigen: a candidate for vaccine development to prevent progression to tuberculosis
Chaouki Benabdessalem, Institut Pasteur de Tunis (Tunisia) - Evaluation of the immunogenicity of a promising vaccine regime to identify immune correlates of protection
Nawamin Pinpathomrat, University of Oxford (UK)
- Demonstration of a correlation between the in vitro direct mycobacterial growth inhibition assay (MGIA) and protection from in vivo mycobacterial challenge
Rachel Tanner, University of Oxford (UK) - Altered systemic levels of neutrophil and mast cell granular proteins in tuberculosis-diabetes co-morbidity and changes following treatment
Kadar Abbas Moideen, National Institute of Health-NIRT-International Center for Excellence in Research (India)
Sheesh Mahal
Poster Discussion 2: Diagnostics and Epidemiology
Facilitators: Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK) | Jaya Tyagi, Department of Biotechnology, All India Institute of Medical Sciences (India)
- BCG vaccine as proof-of-concept
Marcel Behr, McGill University (Canada) - Effect of anti-tuberculosis treatment on the systemic levels of matrix metalloproteinases and tissue inhibitors of MMP in tuberculosis – diabetes co-morbidity
Nathella Pavan Kumar, NIH-ICER-NIRT (India)
- The ESAT-6 free IGRA, a companion diagnostic for ESAT-6 based TB vaccines
Morten Ruhwald, Statens Serum Institut (Denmark) - Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis
Srabanti Rakshit, Indian Institute of Science (India) - Proliferative T cell (CD3+Ki67+) response to PPD and M. tuberculosis cell membrane complements the tuberculin skin test for detection of latent TB infection in healthy North Indian hospital contacts
Sudhir Sinha, Sanjay Gandhi Post-graduate Institute of Medical Sciences (India) - CD14+ CD16+ cells as immunological marker for protection in house hold contacts with latent tuberculosis infection
Venkata Sanjeev Kumar Neela, Bhagwan Mahavir Medical Research Centre (India) - Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection
Elisa Nemes, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Updating the recommended age of BCG vaccination? Modelling the potential impact on global paediatric TB mortality
Partho Roy, London School of Hygiene and Tropical Medicine (UK)
Presented by Rebecca Harris, London School of Hygiene and Tropical Medicine (UK) - Do we have identified target groups and a population based strategy for vaccination against tuberculosis to cut down transmission?
U.D. Gupta, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (India)
- TB infection among household contacts: Preventive therapy for all?
Chandra Kumar Dolla, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India) - Infection free “resistors” among household contacts of culture-confirmed adult pulmonary TB cases
Vidya Mave, Byramjee Jeejeebhoy Government Medical College – Johns Hopkins University Clinical Research Site (India) - Incidence of Mycobacterium tuberculosis infection among household contacts of adult pulmonary tuberculosis cases in India
Mandar Paradkar, Byramjee Jeejeebhoy Government Medical College Clinical Research Site (India)
Mamtaz Mahal
Poster Viewing: Novel Vaccine Concepts; Chemistry, Manufacturing and Controls
Novel Vaccine Concepts
- The impact of previous BCG vaccination in enhancing the effectiveness of tuberculosis drugs to control mycobacterial growth ex-vivo
Satria Arief Prabowo, London School of Hygiene and Tropical Medicine (UK) - The role of DPP4 and antagonist CXCL10 in the pathogenesis of TB, an opportunity for vaccines and HDT?
Morten Ruhwald, Statens Serum Institut (Denmark) - Mycobacterium tuberculosis H37Rv cell wall isolated poly L-glutamines as novel Th1-biased adjuvant
Manish Gupta, Jawaharlal Nehru University (India) - De novo arginine biosynthesis pathway of Mycobacterium tuberculosis: A novel drug target and potential vaccine candidate
Sangeeta Tiwari, Albert Einstein College of Medicine (USA) - Epitope-based vaccine design for Mycobacterium tuberculosis strains through pan-genomic reverse vaccinology
Ravina Madhulitha Nalamolu, Sri Venkateswara Institute of Medical Sciences University (India) - Development of a recombinant BCG vaccine expressing a monomeric form of ESAT-6
Makram Essafi, Institut Pasteur de Tunis (Tunisia) - Insights into mycobacterial membrane vesicles: a potential subunit vaccine candidate
Praapti Jayaswal, Translational Health Science and Technology Institute (India) - Assessment of the protective effect, against tuberculosis, of a new vaccine composition
Rania Bouzeyen, Insitut Pasteur de Tunis (Tunisia) - Assessing the immunological activity of the fusion protein consisted of the major secretory protein of Mycobacterium tuberculosis
Hyun Shik Bae, Chungnam National University (South Korea) - Synthetic polysaccharide conjugate vaccines expressing Mycobacterium tuberculosis antigens induce high-titer antibody responses in mice, guinea pigs, and rabbits
Dominick Laddy, Aeras (USA) - Rv2882c-Rv20xxc, a novel immunostimulatory antigen of Mycobacterium tuberculosis, activates bone-marrow derived dendritic cell
Ki-Won Shin, College of Medicine, Chungnam National University (South Korea) - Mycobacterium tuberculosis protein Rv2299c fused-ESAT-6 subunit vaccine confers improved protection against the hypervirulent strain HN878 in mice
Seunga Choi, College of Medicine, Chungnam National University (South Korea) - Evaluation of attenuated strains as auxotrophic vaccines against Mycobacterium tuberculosis
Tannu Priya Gosain, Translational Health Science and Technology Institute (India)
Chemistry, Manufacturing and Controls
- Miniaturized fluorescence adapter for fluorescence sputum smear microscopy using bright-field microscope
Mamta Rani, IIT Delhi (India)
Presented by Pooja Singh, IIT Delhi (India) - Development of an innovative, rapid, affordable and automated system for selective enrichment, isolation and detection of MTB in sputum sample
Saumya Singh, IIT Delhi (India) - Comparison of pellicle and liquid grown BCG reference strains in standard BCG batch release assays and protection studies
Megan Fitzpatrick, Aeras (USA)
17:45 – 18:30
Rani Bagh Lawn
Networking and Refreshments
18:30 - 20:00
Shahjehan
Inaugural Ceremony
Co-Chairs: Nick Drager, Executive Director, TuBerculosis Vaccine Initiate (Netherlands) | Lucica Ditiu, Executive Director, Stop TB Partnership (Switzerland)
- Prevention is better than cure: A survivor story (video)
Mona Balani, Touched by TB (India) - Regional efforts to bending the curve (video)
Poonam Khetrapal Singh, WHO Regional Director for South-East Asia (India) - Translating rhetoric into action: Transforming the global TB response (video)
Soumya Swaminathan Deputy Director General of Programmes, World Health Organization (Switzerland) - Research, innovation and partnership as the pathway to success (video)
Ashutosh Sharma, Secretary, Department of Biotechnology and Department of Science and Technology, Ministry of Science & Technology (India) - India’s role in TB vaccine research (video)
Preeti Sudan, Secretary, Department of Health and Family Welfare, Government of India & Secretary, Department of Health Researcher & Director-General, Indian Council of Medical Research - India’s mission to strengthen vaccine research (video)
Anupriya Patel, Honourable Minister of State, Ministry of Health & Family Welfare (India)
20:00 – 21:30
Rani Bagh Lawn
Forum Dinner
Wednesday, 21 February 2018
9:00 - 11:00
Shahjehan
Shahjehan Plenary Session 2: Clinical Development of New TB Vaccines
Co-Chairs: Souleymane Mboup, Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations (Senegal) | Sanjay Mehendale, Indian Council of Medical Research (India)
- A critical juncture in tuberculosis vaccine clinical development: overview of progress
Ann M. Ginsberg, Aeras (USA) - Community engagement and Good Participatory Practice guidelines for TB vaccine research and development
Moses Zimba, Centre for Infectious Disease Research in Zambia (Zambia) - Evaluating potential vaccine(s) in preventing disease in healthy household contacts of TB patients
Kavita Singh, Multi Vaccines Development Program (India) - A new TB vaccine on the horizon
Umesh Shaligram, Serum Institute of India (India)
Presented by Prasad Kulkarni - Prevention of infection with Mycobacterium tuberculosis by H4:IC31 vaccination or BCG revaccination in healthy adolescents: results of a randomized controlled trial
Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
11:00 - 11:30
Coffee / Tea Break
11:30 - 13:00
Shahjehan
Breakout Session 1: Basic Science Research
Co-chairs: Katrin Eichelberg, National Institute for Allergy and Infectious Diseases (USA) | Rajesh Gohale, National Institute of Immunology (India)
- How EsxH controls host cellular responses to Mycobacterium tuberculosis?
Ekansh Mittal, Washington University School of Medicine (USA) - Elevated cyclic AMP inhibits Mycobacterium tuberculosis-stimulated T cell IFN-γ Secretion through type I protein kinase A
Buka Samten, University of Texas Health Science Center at Tyler (USA) - A TOLLIP deficiency allele, rs5743854, is associated with decreased lncRNA TOLLIP-AS1 expression, BCG-specific T-cell memory phenotypes, and increased TB susceptibility
Javeed Ali Shah, University of Washington (USA) - Pulmonary mucosal BCG vaccination shows protection of infection in a novel repeated ultra-low dose challenge model in rhesus macaques
Frank A.W. Verreck, Biomedical Primate Research Centre (Netherlands) - Memory, activation and functional profiles of Mycobacterium tuberculosis-specific CD4 T cells in recent QFT converters
Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Protein kinase G confers survival advantage to Mycobacterium tuberculosis during latency like conditions
Mehak Zahoor Khan, National Institute of Immunology (India)
Jehangir
Breakout Session 2: Clinical Research
Co-chairs: Sanjay Gurunathan, Sanofi Pasteur (USA) | Randeep Guleria, All India Institute of Medical Sciences (India)
- DAR-901: an inactivated whole cell NTM booster vaccine
C. Fordham von Reyn, Geisel School of Medicine at Dartmouth (USA) - A randomized, double-blind, dose-escalation clinical trial of MTBVAC compared to BCG Vaccine SSI, in newborns living in a tuberculosis endemic region
Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Clinical development of ID93+GLA-SE as a prophylactic or therapeutic vaccine for tuberculosis
Tracey Ann Day, Infectious Disease Research Institute (USA) - Use of oral inactivated Mycobacterium manresensis to reduce the risk of TB
Pere-Joan Cardona, Institut Germans Trias i Pujol (Spain) - Phase III, placebo-controlled, 2:1 randomized, double-blinded trial of tableted immunotherapeutic TB vaccine (V7) containing 10 microgram of heat-killed M. vaccae
Aldar S. Bourinbair, Immunitor LLC (Mongolia) - Randomized open phase 1 trial of TB/FLU-01L vaccine administrated intranasally or sublingually for immunotherapy of pulmonary tuberculosis
Marina Stukova, Research Institute of Influenza (Russia)
13:00 – 14:00
Rani Bagh Lawn
Lunch
14:00 – 16:00
Shahjehan
Plenary Session 3: Novel Approaches to TB Vaccine Research & Development
Co-chairs: JoAnne Flynn, University of Pittsburgh (USA) | Anil Tyagi, Guru Gobind Singh Indraprastha University (India)
- The route of BCG vaccination determines immunity and protection against Mycobacterium tuberculosis infection in non-human primates
Robert Seder, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA) - Vaccination following mycobacterial exposure
Thomas Scriba, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Cytomegalovirus (CMV)-based TB vaccines
Aurelio Bonavia, Vir Biotechnology (USA) - Nucleic acid vaccines for tuberculosis
Jeffrey Ulmer, GSK Vaccines (USA) - Protective potential of Mycobacterium indicus pranni (MIP) and the underlying mechanisms in animal models of tuberculosis
Sangeeta Bhaskar, National Institute of Immunology (India)
16:00 - 16:30
Coffee / Tea Break
16:30 – 18:00
Roshanara
Poster Discussion 3: Preclinical Research
Facilitators: Damilo Casimiro, former Aeras (USA) | Sarala Balachandran, Council of Scientific and Industrial Research (India)
- Early and local immune mechanisms of TB disease progression and control upon ultra-low dose infection in rhesus versus cynomolgus macaques
Karin Djikman, Biomedical Primate Research Centre (Netherlands) - Experimental evaluation of a novel microneedle device for BCG vaccination
Jungho Kim, International Tuberculosis Research Center (South Korea)
Presented by Jake Whang, International Tuberculosis Research Center (South Korea) - Role of BCG encapsulated alginate particles in activation of bone marrow derived dendritic cells for providing better immune response against TB
Ashwani Kesarwani, National Institute of Immunology; Jamia Handard (India) - bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs
Ritika Kar Bahal, University of Delhi South Campus (India) - Animal dose response curve predicts lower optimal tuberculosis vaccine dose in humans: The use of vaccine Immunostimulation/ Immunodynamic modelling methods to inform vaccine dose decision-making
Sophie Rhodes, London School of Hygiene and Tropical Medicine (UK)
Presented by Richard White, London School of Hygiene and Tropical Medicine (UK) - T cell immunity in the lung and protection following aerosol, intravenous, or intradermal administration of BCG in nonhuman primates
Patricia Darrah, National Institute of Immunology and Infectious Diseases, National Institutes of Health (USA) - A recombinant BCG-LTAK63 strain induces increased innate and long-term immunity correlating with enhanced protection against tuberculosis
Luciana Leite, Instituto Butantan (Brazil) - Recombinant BCG-LTAK63 strain induces lower immunopathological effects and superior protection against tuberculosis in BALB/c and C57BL/6 mice
Carina Santos, Instituto Butantan (Brazil) - Intransal vaccination with Mycobacterium indicus pranii leads to infiltration of protective memory T-cells in lung airway lumen
Ananya Gupta, National Institute of Immunology (India) - Boosting with recombinant MVA expressing α-crystallin antigen of M. tuberculosis augments the protection imparted by BCG against tuberculosis in guinea pigs
Prachi Nangpal, University of Delhi South Campus (India) - A single dose nanoparticulate vaccine approach against tuberculosis
Manish Gupta, Jawaharlal Nehru University (India) - Passive vaccination with human IgA protects against MDR-TB infection in mice
Andy Tran, St. George’s University of London (UK)
Sheesh Mahal
Poster Discussion 4: Clinical Research and Community Engagement
Facilitators: Souleymane Mboup, Institut de Recherche en Sante, de Surveillance Epidemiologique et de Formations (Senegal) | Lorraine Misquith, Lawyers Collective; Global Coalition of TB Activists (India)
- Immunogenicity of AERAS-404 or BCG revaccination in a prevention of established M. tuberculosis infection efficacy trial
Virginie Rozot, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Phase 1 clinical trial to evaluate the safety and immunogenicity of an adenovirus-based tuberculosis vaccine (Ad5Ag85A) administered by aerosol to healthy volunteers
Fiona Smaill, McMaster University (Canada) - Dose definition of the novel TB vaccine ID93 + GLA-SE for TB endemic countries
Adam Penn-Nicholson, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - The Toll-like receptor 4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine
Tracey Ann Day, Infectious Disease Research Institute (USA) - Safety and immunogenicity of H56:IC31 in HIV negative adults with and without latent tuberculosis(TB) infection
Angelique Kany Kany Luabeya, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Impact of implementing an effective community engagement strategy on retention rates in a Phase 2b TB disease prevention vaccine trial in South Africa, Zambia, and Kenya
Anja van der Westhuizen, Aeras Africa (South Africa) - Building a portfolio of community engagement projects to enhance TB
Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Drama as a community engagement tool to raise TB awareness
Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Leveraging libraries to raise awareness about TB on World TB Day
Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Using eCompliance for tracking patients and ensuring accuracy of data in vaccine trials
Shelly Batra, Operation ASHA (India)
Mamtaz Mahal
Poster Viewing: Basic Science Research, Biomarkers and Correlates, Epidemiology
Basic Science Research; Biomarkers and Correlates of Immunity and Protection
- Functional, antigen-specific stem cell-like memory (Tscm) CD4+ T cells are induced by human Mycobacterium tuberculosis infection
Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) - Activation of L-type voltage gated calcium channel in macrophages suppresses protective responses during Mycobacterium tuberculosis infection
Deepika Sharma, University of Delhi (India) - Role of phosphorylation on secretion in Mycobacterium tuberculosis and its impact on its survival
Basanti Malakar, National Institute of Immunology (India) - Challenges in detecting TB drug resistance in a field setting in Southwestern Uganda
Patrick Orikiriza, Mbarara University of Science and Technology (Uganda) - Calcimycin induced autophagy decreases mycobacterial growth in THP-1 cells through P2RX7 dependent pathway mediated by intracellular calcium
Shradha Mawatwal, National Institute of Technology, Rourkela (India) - Phenotypic adaptation to drug treatment in Mycobacterium tuberculosis is mediated by DNA gyrase
Eira Choudhary, Translational Health and Science Technology Institute (India) - Assessment of anti-mycobacterial activity of some selected Congolese medicinal plants
Gedeon Ngiala Bongo, University of Kinshasa (Democratic Republic of Congo) - Various aspects of GTPases towards its essentiality in survival and pathogenesis of Mycobacterium tuberculosis H37Rv
Shivangi, CSIR-Institute of Genomics and Integrative Biology (India) - Cytokines, matrix metalloproteinases, angiogenic factors and acute phase proteins as biomarkers in tuberculous lymphadenitis
Gokul Raj Kathamuthu, National Institute for Research in Tuberculosis (NIRT)-NIH-ICER (India) - Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis
Hyejon Lee, Yonsei University College of Medicine (South Korea)
Presented by Bora Sim, Yonsei University College of Medicine (South Korea)
Epidemiology
- Sputum sample collection for diagnosis of pediatric pulmonary tuberculosis, does method and site of sample collection matter?
Willy Ssengooba, Makerere University (Uganda) - Tuberculosis massive active case discovery in East Jakarta 2016-2017: the role of Ketuk Pintu Layani Dengan Hati (KPLDH) and Juru Pemantau Batuk (Jumantuk) cadre programs
Ngabila Salama, East Jakarta Health Office (Indonesia) - Clinical Profile Of tuberculous meningitis in a tertiary care center in India
Anita Basavaraj, BJGMC (India)
18:00 - 20:00
Shahjehan, Mumtaz Mehal, Sheesh Mahal, and Roshanara
Networking Reception and Poster Viewing
Cultural performance followed by networking and poster viewing
Posters on display in Mumtaz Mahal, Sheesh Mahal, and Roshanara
Food and drink stations will be located in Shahjehan and Roshanara
Thursday, 22 February 2018
7:15 - 8:45
Jenhangir
Satellite Session: Panel Discussion and Audience Q&A on the H4:IC31®/BCG Revaccination POI Trial Results
Organized by Sanofi Pasteur and Aeras
Panel discussion featuring:
- Ann Ginsberg, Aeras, USA (moderator)
- Gavin Churchyard, Aurum Institute (South Africa)
- Carl Dieffenbach, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)
- Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
- Sanjay Gurunathan, Sanofi Pasteur (USA)
Click here to view the video of the session
9:00 - 11:00
Shahjehan
Plenary Session 4: The Cutting Edge: Translating Scientific Advances into New TB Vaccines
Co-Chairs: Peter Andersen, Statens Serum Institute (Denmark) | G.P. Talwar, Talwar Research Foundation (India)
- Predictive biosignatures to improve tuberculosis vaccine development
Stefan H.E. Kaufmann, Max Planck Institute of Infection Biology (Germany) - Harnessing the power of innate immunity in vaccines against TB
Maziar Divangahi, McGill University (Canada) - Donor unrestricted T-cells (DURTS)
David Lewinsohn, Oregon Health & Science University (USA) - Tissue resident memory T-cells in infection and inflammation
Chang Ook Park, Yonsei University College of Medicine (South Korea) - Targeting checkpoint inhibitor-PD-1 for enhancing efficacy of therapeutic vaccines in tuberculosis
Dipendra K Mitra, All India Institute of Medical Sciences (India)
11:00 - 11:30
Coffee / Tea Break
11:30 - 13:00
Shahjehan
Breakout Session 3: Novel Vaccine Concepts and Preclinical Research
Co-Chairs: Luciana Leite, Instituto Butantan (Brazil) | Seyed E. Hasnain, Jamia Hamdard (India)
- Stress-response deficient attenuated Mycobacterium tuberculosis as next-gen TB vaccines
Deepak Kaushal, Tulane National Primate Research Center (USA) - Mechanisms of attenuation and protection of MTBVAC, a live attenuated tuberculosis vaccine moving to efficacy clinical trials
Carlos Martin, University of Zaragoza (Spain) - Increased efficacy of chemotherapy against Mycobacterium tuberculosis by additive immunotherapy using a multistage MVA vaccine
Stephane Leung-Theung-Long, Transgene (France) - Immunogenicity and efficacy evaluation of multiple ChAd3-5Ag ± MVA-5Ag prime-boost vaccine regimens in rhesus macaques
Agnes Laurence Chenine, Aeras (USA) - Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved tuberculosis protection
Matthias I. Gröschel, Institute Pasteur, Paris (France); University Medical Center Groningen (Netherlands) - Novel mucosal TB vaccine candidates generated by EMI-TB consortium
Rajko Reljic, St. George’s University of London (UK)
Presented by Gil Diogo, St. George’s University of London (UK)
Jehangir
Breakout Session 4: Biomarkers, Correlates, and Epidemiology
Co-Chairs: Gerald Voss, TuBerculosis Vaccine Initiative (Belgium) | Vijaya Lakshmi Valluri, Bhagwan Mahavir Medical Research Center (India)
- NK cells and memory-like NK cells as immunological markers of protection against latent TB conversion in household contacts of TB patients
Kamakshi Prudhula Devalraju, Bhagwan Mahavir Medical Research Centre (India) - Gene expression profiles of pediatric tuberculosis patients and exposed controls from India
Jeffrey A. Tornheim, Johns Hopkins University School of Medicine (USA) - Evaluating immune correlates of risk of Mycobacteria tuberculosis infection in humans
Iman Satti, University of Oxford (UK) - Maximising impact of the TB vaccine pipeline – mathematical modelling to inform target product profiles
Rebecca Claire Harris, London School of Hygiene and Tropical Medicine (UK) - Incidence of tuberculosis disease among household contacts of adult pulmonary tuberculosis patients in India – a multi centric cohort study
Sriram Selvaraju, National Institute for Research in Tuberculosis (India) - High risk for tuberculosis infections among medical and nursing trainees in India
Aarti Avinash Kinikar, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)
13:00 – 14:00
Rani Bagh Lawn
Lunch
14:00 - 16:30
Shahjehan
Plenary Session 5: Partnering for Progress and Innovation
Co-Chairs/Facilitators: Ole Olesen, European & Developing Countries Clinical Trials Partnership (Netherlands) | Renu Swarup, Biotechnology Industry Research Assistance Council; Department of Biotechnology (India)
Roundtable discussion featuring:
- Fareed Abdullah, South African Medical Research Council (South Africa)
- Shelly Batra, Operation ASHA (India)
- Michel Kazatchkine, Global Health Centre, Graduate Institute for International Development Studies (Switzerland)
- Rajiv I. Modi, Chairman of the Confederation of Industry National Council on Pharmaceuticals; Cadila Pharmaceuticals (India)
- Jacqueline Shea, Aeras (USA)
Closing Session
Co-Chairs: Danilo Casimiro, former Aeras (USA) | David Lewinsohn, Stop TB Partnership Working Group on New Vaccines (USA) | Nick Drager, Tuberculosis Vaccine Initiative (Netherlands)
Closing Address (video)
Lucica Ditiu, Stop TB Partnership (Switzerland)
Friday, 23 February 2018
Site Visits
Site visits to four local institutions involved in TB research and care are offered to 5th Global Forum delegates.
8:30 – 12:00 Operation ASHA
8:30 – 14:00 Translational Health Science and Technology Institute
9:00 – 11:30 International Centre for Genetic Engineering and Biotechnology
9:30 – 13:00 National Institute for Tuberculosis and Respiratory Diseases
Click here to view the 5th Global Forum program-at-a-glance.
Click here to download the session program
Click here to download the poster program